Highlights Hunan Er-Kang Pharmaceutical Co., Ltd

Equities

300267

CNE100001781

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
2.4 ^CNY	-.--%		-2.44%	-25.23%

26/04	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	24/04	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	22/23/22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023	03/23/03	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan	20/23/20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
ER-KANG Pharma Earmarks $140 Million for Lithium Carbonate Factory; Shares Gain 7%	17/22/17	MT
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Profit Distribution Proposal for 2021	29/22/29	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	27/22/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.	28/21/28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	26/21/26	CI
Xu Zhiqi completed the acquisition of 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd from Hunan Shuaijia Investment Co., Ltd.	21/21/21	CI
An unknown buyer agreed to acquire 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd for approximately CNY 200 million.	02/21/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hunan Er-Kang Pharmaceutical Co., Ltd

Equities

300267

CNE100001781

Highlights

Filters